Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

(MedPage Today) — CHICAGO — A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found.
In QWINT-1, there was a similar HbA1c reduction with…

Source link : https://www.medpagetoday.com/meetingcoverage/ada/116189

Author :

Publish date : 2025-06-22 19:56:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

‘5 Years, 10 Years at Most, I’m Going to Retire’: What We Heard This Week

Related Posts

One in Four Clinicians Battle Self-Medicated Insomnia

Mounjaro weight loss jab available at GPs

Nightmares linked to faster biological ageing and early death

Once-Weekly Efsitora Noninferior to Daily Insulin in T2D

‘5 Years, 10 Years at Most, I’m Going to Retire’: What We Heard This Week

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

One in Four Clinicians Battle Self-Medicated Insomnia

Mounjaro weight loss jab available at GPs

Nightmares linked to faster biological ageing and early death

Once-Weekly Efsitora Noninferior to Daily Insulin in T2D

‘5 Years, 10 Years at Most, I’m Going to Retire’: What We Heard This Week

Once-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes

Combo Semaglutide-Amylin Analogue Boosts Weight Loss Regardless of Diabetes

Can Behavioral Support Enhance CGM Use in T1D?

Categories

Archives